FREE SHIPPING over $40
OVER 10000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Viruses2019; 11(9); 807; doi: 10.3390/v11090807

Approach to Strain Selection and the Propagation of Viral Stocks for Venezuelan Equine Encephalitis Virus Vaccine Efficacy Testing under the Animal Rule.

Abstract: Licensure of a vaccine to protect against aerosolized Venezuelan equine encephalitis virus (VEEV) requires use of the U.S. Food and Drug Administration (FDA) Animal Rule to assess vaccine efficacy as human studies are not feasible or ethical. An approach to selecting VEEV challenge strains for use under the Animal Rule was developed, taking into account Department of Defense (DOD) vaccine requirements, FDA Animal Rule guidelines, strain availability, and lessons learned from the generation of filovirus challenge agents within the Filovirus Animal Nonclinical Group (FANG). Initial down-selection to VEEV IAB and IC epizootic varieties was based on the DOD objective for vaccine protection in a bioterrorism event. The subsequent down-selection of VEEV IAB and IC isolates was based on isolate availability, origin, virulence, culture and animal passage history, known disease progression in animal models, relevancy to human disease, and ability to generate sufficient challenge material. Methods for the propagation of viral stocks (use of uncloned (wild-type), plaque-cloned, versus cDNA-cloned virus) to minimize variability in the potency of the resulting challenge materials were also reviewed. The presented processes for VEEV strain selection and the propagation of viral stocks may serve as a template for animal model development product testing under the Animal Rule to other viral vaccine programs. This manuscript is based on the culmination of work presented at the "Alphavirus Workshop" organized and hosted by the Joint Vaccine Acquisition Program (JVAP) on 15 December 2014 at Fort Detrick, Maryland, USA.
Get Full Text
Publication Date: 2019-08-31 PubMed ID: 31480472PubMed Central: PMC6784384DOI: 10.3390/v11090807Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Research Support
  • N.I.H.
  • Extramural
  • Research Support
  • U.S. Gov't
  • Non-P.H.S.

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research article outlines a procedure for selecting strains and propagating viral stocks of Venezuelan equine encephalitis virus (VEEV) for testing vaccine effectiveness, adhering to the FDA Animal Rule due to the unfeasibility and lack of ethics in carrying out human studies.

Venezuelan Equine Encephalitis Virus and the FDA Animal Rule

  • The study focuses on Venezuelan equine encephalitis virus (VEEV), a virus that can have severe effects when aerosolized and thus needs an effective vaccine for protection. However, testing the effectiveness of such a vaccine in humans is neither feasible nor ethical.
  • Due to these complications, the researchers used the U.S. Food and Drug Administration’s (FDA) Animal Rule to assess the vaccine’s efficacy. The Animal Rule allows for drug approval based on animal studies when it isn’t feasible or ethical to conduct human trials.

Research Approach

  • The researchers developed an approach to select VEEV challenge strains for use under the Animal Rule, taking into account factors like the Department of Defense (DOD) vaccine requirements, FDA Animal Rule guidelines, availability of the strain, and valuable lessons derived from strain generation for the Filovirus Animal Nonclinical Group (FANG).
  • Initially, they selected VEEV IAB and IC epizootic varieties based on DOD’s objective to protect against a bioterrorism event.
  • Further down-selection of VEEV IAB and IC isolates was based on factors including availability, origin, virulence, culture and animal passage history, known disease progression in animal models, relevancy to human disease, and the ability to generate enough challenge material.

Propagation of Viral Stocks

  • The researchers also examined the methods for the propagation of viral stocks. They compared the use of uncloned (wild-type) virus, plaque-cloned virus, and cDNA-cloned virus.
  • The objective was to minimize variability in the potency of the resulting challenge materials.

Implication of the Study

  • The established processes for VEEV strain selection and the propagation of viral stocks could potentially serve as a blueprint for animal model development and product testing within the framework of the Animal Rule for other viral vaccine programs.
  • This work culminated in a presentation at the “Alphavirus Workshop” organized by the Joint Vaccine Acquisition Program (JVAP) on 15 December 2014, in Fort Detrick, Maryland, USA.

Cite This Article

APA
Rusnak JM, Glass PJ, Weaver SC, Sabourin CL, Glenn AM, Klimstra W, Badorrek CS, Nasar F, Ward LA. (2019). Approach to Strain Selection and the Propagation of Viral Stocks for Venezuelan Equine Encephalitis Virus Vaccine Efficacy Testing under the Animal Rule. Viruses, 11(9), 807. https://doi.org/10.3390/v11090807

Publication

Viruses
ISSN: 1999-4915
NlmUniqueID: 101509722
Country: Switzerland
Language: English
Volume: 11
Issue: 9
PII: 807

Researcher Affiliations

Rusnak, Janice M
  • Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), Joint Project Manager-Medical Countermeasure Systems (JMP-MCS), Joint Vaccine Acquisition Program (JVAP), 1564 Freedman Drive, Fort Detrick, MD 21702, USA. Janice.m.rusnak.ctr@mail.mil.
Glass, Pamela J
  • Department of Virology, United States Army Medical Research Institute of Infectious Diseases (USAMRIID), 1425 Porter Street, Fort Detrick, MD 21702, USA.
Weaver, Scott C
  • Institute for Human Infections and Immunity, World Reference Center for Emerging Viruses and Arboviruses and Department of Microbiology and Immunology, University of Texas Medical Branch, 301 University Boulevard, Galveston, TX 77555, USA.
Sabourin, Carol L
  • Battelle Biomedical Research Center, 1425 Plain City-Georgesville Road, West Jefferson, OH 43162, USA.
Glenn, Andrew M
  • Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), Joint Project Manager-Medical Countermeasure Systems (JMP-MCS), Joint Vaccine Acquisition Program (JVAP), 1564 Freedman Drive, Fort Detrick, MD 21702, USA.
Klimstra, William
  • Center for Vaccine Research, University of Pittsburgh, 3501 Fifth Avenue, Pittsburgh, PA 15261, USA.
Badorrek, Christopher S
  • Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), Joint Project Manager-Medical Countermeasure Systems (JMP-MCS), Joint Vaccine Acquisition Program (JVAP), 1564 Freedman Drive, Fort Detrick, MD 21702, USA.
Nasar, Farooq
  • Department of Virology, United States Army Medical Research Institute of Infectious Diseases (USAMRIID), 1425 Porter Street, Fort Detrick, MD 21702, USA.
Ward, Lucy A
  • Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), Joint Project Manager-Medical Countermeasure Systems (JMP-MCS), Joint Vaccine Acquisition Program (JVAP), 1564 Freedman Drive, Fort Detrick, MD 21702, USA.

MeSH Terms

  • Animals
  • Disease Models, Animal
  • Encephalitis Virus, Venezuelan Equine / genetics
  • Encephalitis Virus, Venezuelan Equine / immunology
  • Encephalitis Virus, Venezuelan Equine / pathogenicity
  • Encephalomyelitis, Venezuelan Equine / prevention & control
  • Encephalomyelitis, Venezuelan Equine / virology
  • Guidelines as Topic
  • Humans
  • Immunization Programs / methods
  • Immunization Programs / standards
  • Viral Vaccines / therapeutic use
  • Virology / methods

Conflict of Interest Statement

This work was co-written by employees of the U.S. Government (JR, AG, CB, LW, PG, and FN) as part of their official duties. Opinions, interpretations, conclusions, and recommendations are those of the authors and are not necessarily endorsed by the U.S. Army. The authors declare no conflict of interest.

References

This article includes 91 references
  1. Weaver SC, Ferro C, Barrera R, Boshell J, Navarro JC. Venezuelan equine encephalitis.. Annu Rev Entomol 2004;49:141-74.
    doi: 10.1146/annurev.ento.49.061802.123422pubmed: 14651460google scholar: lookup
  2. Randall R, Mills JW. FATAL ENCEPHALITIS IN MAN DUE TO THE VENEZUELAN VIRUS OF EQUINE ENCEPHALOMYELITIS IN TRINIDAD.. Science 1944 Mar 17;99(2568):225-6.
    doi: 10.1126/science.99.2568.225pubmed: 17844380google scholar: lookup
  3. Ehrenkranz NJ, Ventura AK. Venezuelan equine encephalitis virus infection in man.. Annu Rev Med 1974;25:9-14.
    doi: 10.1146/annurev.me.25.020174.000301pubmed: 4824504google scholar: lookup
  4. Aguilar PV, Estrada-Franco JG, Navarro-Lopez R, Ferro C, Haddow AD, Weaver SC. Endemic Venezuelan equine encephalitis in the Americas: hidden under the dengue umbrella.. Future Virol 2011;6(6):721-740.
    doi: 10.2217/fvl.11.50pmc: PMC3134406pubmed: 21765860google scholar: lookup
  5. Bowen GS, Fashinell TR, Dean PB, Gregg MB. Clinical aspects of human Venezuelan equine encephalitis in Texas.. Bull Pan Am Health Organ 1976;10(1):46-57.
    pubmed: 949558
  6. Rivas F, Diaz LA, Cardenas VM, Daza E, Bruzon L, Alcala A, De la Hoz O, Caceres FM, Aristizabal G, Martinez JW, Revelo D, De la Hoz F, Boshell J, Camacho T, Calderon L, Olano VA, Villarreal LI, Roselli D, Alvarez G, Ludwig G, Tsai T. Epidemic Venezuelan equine encephalitis in La Guajira, Colombia, 1995.. J Infect Dis 1997 Apr;175(4):828-32.
    doi: 10.1086/513978pubmed: 9086137google scholar: lookup
  7. U.S. Food and Drug Administration. Product Development under the Animal Rule. Guidance for Industry.. 2015.
  8. Powers AM, Huang HV, Roehrig JT, Strauss EG, Weaver SC. Togaviridae. Virus Taxonomy: Classification and Nomenclature of Viruses: Ninth Report of the International Committee on Taxonomy of Viruses 2011;pp. 1103–1110.
  9. Hirschberg R, Ward LA, Kilgore N, Kurnat R, Schiltz H, Albrecht MT, Christopher GW, Nuzum E. Challenges, progress, and opportunities: proceedings of the filovirus medical countermeasures workshop.. Viruses 2014 Jul 9;6(7):2673-97.
    doi: 10.3390/v6072673pmc: PMC4113787pubmed: 25010768google scholar: lookup
  10. Anishchenko M, Paessler S, Greene IP, Aguilar PV, Carrara AS, Weaver SC. Generation and characterization of closely related epizootic and enzootic infectious cDNA clones for studying interferon sensitivity and emergence mechanisms of Venezuelan equine encephalitis virus.. J Virol 2004 Jan;78(1):1-8.
    doi: 10.1128/JVI.78.1.1-8.2004pmc: PMC303380pubmed: 14671082google scholar: lookup
  11. Anishchenko M, Bowen RA, Paessler S, Austgen L, Greene IP, Weaver SC. Venezuelan encephalitis emergence mediated by a phylogenetically predicted viral mutation.. Proc Natl Acad Sci U S A 2006 Mar 28;103(13):4994-9.
    doi: 10.1073/pnas.0509961103pmc: PMC1458783pubmed: 16549790google scholar: lookup
  12. Martin DH, Dietz WH, Alvaerez O Jr, Johnson KM. Epidemiological significance of Venezuelan equine encephalomyelitis virus in vitro markers.. Am J Trop Med Hyg 1982 May;31(3 Pt 1):561-8.
    doi: 10.4269/ajtmh.1982.31.561pubmed: 7200732google scholar: lookup
  13. Wang E, Barrera R, Boshell J, Ferro C, Freier JE, Navarro JC, Salas R, Vasquez C, Weaver SC. Genetic and phenotypic changes accompanying the emergence of epizootic subtype IC Venezuelan equine encephalitis viruses from an enzootic subtype ID progenitor.. J Virol 1999 May;73(5):4266-71.
    pmc: PMC104206pubmed: 10196323doi: 10.1128/jvi.73.5.4266-4271.1999google scholar: lookup
  14. Powers AM, Brault AC, Kinney RM, Weaver SC. The use of chimeric Venezuelan equine encephalitis viruses as an approach for the molecular identification of natural virulence determinants.. J Virol 2000 May;74(9):4258-63.
    doi: 10.1128/JVI.74.9.4258-4263.2000pmc: PMC111942pubmed: 10756040google scholar: lookup
  15. Greene IP, Wang E, Deardorff ER, Milleron R, Domingo E, Weaver SC. Effect of alternating passage on adaptation of sindbis virus to vertebrate and invertebrate cells.. J Virol 2005 Nov;79(22):14253-60.
    doi: 10.1128/JVI.79.22.14253-14260.2005pmc: PMC1280187pubmed: 16254360google scholar: lookup
  16. Bronze MS, Huycke MM, Machado LJ, Voskuhl GW, Greenfield RA. Viral agents as biological weapons and agents of bioterrorism.. Am J Med Sci 2002 Jun;323(6):316-25.
    doi: 10.1097/00000441-200206000-00004pubmed: 12074486google scholar: lookup
  17. BERGE TO, GLEISER CA, GOCHENOUR WS Jr, MIESSE ML, TIGERTT WD. Studies on the virus of Venezuelan equine encephalomyelitis. II. Modification by specific immune serum of response of central nervous system of mice.. J Immunol 1961 Nov;87:509-17.
    pubmed: 13867629
  18. Jahrling PB, DePaoli A, Powanda MC. Pathogenesis of a Venezuelan encephalitis virus strain lethal for adult white rats.. J Med Virol 1978;2(2):109-16.
    doi: 10.1002/jmv.1890020205pubmed: 670947google scholar: lookup
  19. TIGERTT WD, DOWNS WG. Studies on the virus of Venezuelan equine encephalomyelitis in Trinidad, W.I. I. The 1943-1944 epizootic.. Am J Trop Med Hyg 1962 Nov;11:822-34.
    doi: 10.4269/ajtmh.1962.11.822pubmed: 13985028google scholar: lookup
  20. Powers AM, Oberste MS, Brault AC, Rico-Hesse R, Schmura SM, Smith JF, Kang W, Sweeney WP, Weaver SC. Repeated emergence of epidemic/epizootic Venezuelan equine encephalitis from a single genotype of enzootic subtype ID virus.. J Virol 1997 Sep;71(9):6697-705.
    pmc: PMC191949pubmed: 9261393doi: 10.1128/jvi.71.9.6697-6705.1997google scholar: lookup
  21. France JK, Wyrick BC, Trent DW. Biochemical and antigenic comparison of the envelope glycoproteins of Venezuelan equine encephalomyelitis virus strains.. J Gen Virol 1979 Sep;44(3):725-40.
    doi: 10.1099/0022-1317-44-3-725pubmed: 119035google scholar: lookup
  22. Kinney RM, Johnson BJ, Brown VL, Trent DW. Nucleotide sequence of the 26 S mRNA of the virulent Trinidad donkey strain of Venezuelan equine encephalitis virus and deduced sequence of the encoded structural proteins.. Virology 1986 Jul 30;152(2):400-13.
    doi: 10.1016/0042-6822(86)90142-Xpubmed: 3088830google scholar: lookup
  23. Weaver SC, Salas R, Rico-Hesse R, Ludwig GV, Oberste MS, Boshell J, Tesh RB. Re-emergence of epidemic Venezuelan equine encephalomyelitis in South America. VEE Study Group.. Lancet 1996 Aug 17;348(9025):436-40.
    doi: 10.1016/S0140-6736(96)02275-1pubmed: 8709783google scholar: lookup
  24. Wang E, Bowen RA, Medina G, Powers AM, Kang W, Chandler LM, Shope RE, Weaver SC. Virulence and viremia characteristics of 1992 epizootic subtype IC Venezuelan equine encephalitis viruses and closely related enzootic subtype ID strains.. Am J Trop Med Hyg 2001 Jul;65(1):64-9.
    doi: 10.4269/ajtmh.2001.65.64pubmed: 11504410google scholar: lookup
  25. Brault AC, Powers AM, Weaver SC. Vector infection determinants of Venezuelan equine encephalitis virus reside within the E2 envelope glycoprotein.. J Virol 2002 Jun;76(12):6387-92.
    doi: 10.1128/JVI.76.12.6387-6392.2002pmc: PMC136209pubmed: 12021373google scholar: lookup
  26. Brault AC, Powers AM, Medina G, Wang E, Kang W, Salas RA, De Siger J, Weaver SC. Potential sources of the 1995 Venezuelan equine encephalitis subtype IC epidemic.. J Virol 2001 Jul;75(13):5823-32.
    doi: 10.1128/JVI.75.13.5823-5832.2001pmc: PMC114297pubmed: 11390583google scholar: lookup
  27. Rico-Hesse R, Roehrig JT, Trent DW, Dickerman RW. Genetic variation of Venezuelan equine encephalitis virus strains of the ID variety in Colombia.. Am J Trop Med Hyg 1988 Jan;38(1):195-204.
    doi: 10.4269/ajtmh.1988.38.195pubmed: 3341520google scholar: lookup
  28. Rico-Hesse R, Weaver SC, de Siger J, Medina G, Salas RA. Emergence of a new epidemic/epizootic Venezuelan equine encephalitis virus in South America.. Proc Natl Acad Sci U S A 1995 Jun 6;92(12):5278-81.
    doi: 10.1073/pnas.92.12.5278pmc: PMC41677pubmed: 7777497google scholar: lookup
  29. Vilcarromero S, Aguilar PV, Halsey ES, Laguna-Torres VA, Razuri H, Perez J, Valderrama Y, Gotuzzo E, Suarez L, Cespedes M, Kochel TJ. Venezuelan equine encephalitis and 2 human deaths, Peru.. Emerg Infect Dis 2010 Mar;16(3):553-6.
    doi: 10.3201/eid1603.090970pmc: PMC3322018pubmed: 20202445google scholar: lookup
  30. Moncayo AC, Lanzaro G, Kang W, Orozco A, Ulloa A, Arredondo-Jiménez J, Weaver SC. Vector competence of eastern and western forms of Psorophora columbiae (Diptera: Culicidae) mosquitoes for enzootic and epizootic Venezuelan equine encephalitis virus.. Am J Trop Med Hyg 2008 Mar;78(3):413-21.
    doi: 10.4269/ajtmh.2008.78.413pubmed: 18337337google scholar: lookup
  31. Weaver SC, Pfeffer M, Marriott K, Kang W, Kinney RM. Genetic evidence for the origins of Venezuelan equine encephalitis virus subtype IAB outbreaks.. Am J Trop Med Hyg 1999 Mar;60(3):441-8.
    doi: 10.4269/ajtmh.1999.60.441pubmed: 10466974google scholar: lookup
  32. Davis NL, Brown KW, Greenwald GF, Zajac AJ, Zacny VL, Smith JF, Johnston RE. Attenuated mutants of Venezuelan equine encephalitis virus containing lethal mutations in the PE2 cleavage signal combined with a second-site suppressor mutation in E1.. Virology 1995 Sep 10;212(1):102-10.
    doi: 10.1006/viro.1995.1458pubmed: 7676619google scholar: lookup
  33. Johnston RE, Smith JF. Selection for accelerated penetration in cell culture coselects for attenuated mutants of Venezuelan equine encephalitis virus.. Virology 1988 Feb;162(2):437-43.
    doi: 10.1016/0042-6822(88)90484-9pubmed: 3341117google scholar: lookup
  34. Bernard KA, Klimstra WB, Johnston RE. Mutations in the E2 glycoprotein of Venezuelan equine encephalitis virus confer heparan sulfate interaction, low morbidity, and rapid clearance from blood of mice.. Virology 2000 Oct 10;276(1):93-103.
    doi: 10.1006/viro.2000.0546pubmed: 11021998google scholar: lookup
  35. Coffey LL, Vasilakis N, Brault AC, Powers AM, Tripet F, Weaver SC. Arbovirus evolution in vivo is constrained by host alternation.. Proc Natl Acad Sci U S A 2008 May 13;105(19):6970-5.
    doi: 10.1073/pnas.0712130105pmc: PMC2383930pubmed: 18458341google scholar: lookup
  36. Gilyard RT. A clinical study of Venezuelan virus equine encephalomyelitis in Trinidad, B.W.I.. JAMA 1945;818:267–277.
  37. Dupuy LC, Richards MJ, Ellefsen B, Chau L, Luxembourg A, Hannaman D, Livingston BD, Schmaljohn CS. A DNA vaccine for venezuelan equine encephalitis virus delivered by intramuscular electroporation elicits high levels of neutralizing antibodies in multiple animal models and provides protective immunity to mice and nonhuman primates.. Clin Vaccine Immunol 2011 May;18(5):707-16.
    doi: 10.1128/CVI.00030-11pmc: PMC3122536pubmed: 21450977google scholar: lookup
  38. Parker MD, Buckley MJ, Melanson VR, Glass PJ, Norwood D, Hart MK. Antibody to the E3 glycoprotein protects mice against lethal venezuelan equine encephalitis virus infection.. J Virol 2010 Dec;84(24):12683-90.
    doi: 10.1128/JVI.01345-10pmc: PMC3004303pubmed: 20926570google scholar: lookup
  39. Reed DS, Glass PJ, Bakken RR, Barth JF, Lind CM, da Silva L, Hart MK, Rayner J, Alterson K, Custer M, Dudek J, Owens G, Kamrud KI, Parker MD, Smith J. Combined alphavirus replicon particle vaccine induces durable and cross-protective immune responses against equine encephalitis viruses.. J Virol 2014 Oct;88(20):12077-86.
    doi: 10.1128/JVI.01406-14pmc: PMC4178741pubmed: 25122801google scholar: lookup
  40. Hart MK, Caswell-Stephan K, Bakken R, Tammariello R, Pratt W, Davis N, Johnston RE, Smith J, Steele K. Improved mucosal protection against Venezuelan equine encephalitis virus is induced by the molecularly defined, live-attenuated V3526 vaccine candidate.. Vaccine 2000 Jul 1;18(26):3067-75.
    doi: 10.1016/S0264-410X(00)00042-6pubmed: 10825611google scholar: lookup
  41. Hunt AR, Frederickson S, Hinkel C, Bowdish KS, Roehrig JT. A humanized murine monoclonal antibody protects mice either before or after challenge with virulent Venezuelan equine encephalomyelitis virus.. J Gen Virol 2006 Sep;87(Pt 9):2467-2476.
    doi: 10.1099/vir.0.81925-0pubmed: 16894184google scholar: lookup
  42. O'Brien LM, Goodchild SA, Phillpotts RJ, Perkins SD. A humanised murine monoclonal antibody protects mice from Venezuelan equine encephalitis virus, Everglades virus and Mucambo virus when administered up to 48 h after airborne challenge.. Virology 2012 May 10;426(2):100-5.
    doi: 10.1016/j.virol.2012.01.038pubmed: 22341308google scholar: lookup
  43. Phillpotts RJ, O'brien L, Appleton RE, Carr S, Bennett A. Intranasal immunisation with defective adenovirus serotype 5 expressing the Venezuelan equine encephalitis virus E2 glycoprotein protects against airborne challenge with virulent virus.. Vaccine 2005 Feb 18;23(13):1615-23.
    doi: 10.1016/j.vaccine.2004.06.056pubmed: 15694514google scholar: lookup
  44. Bennett AM, Lescott T, Phillpotts RJ. Improved protection against Venezuelan equine encephalitis by genetic engineering of a recombinant vaccinia virus.. Viral Immunol 1998;11(3):109-17.
    doi: 10.1089/vim.1998.11.109pubmed: 9918402google scholar: lookup
  45. Bennett AM, Elvin SJ, Wright AJ, Jones SM, Phillpotts RJ. An immunological profile of Balb/c mice protected from airborne challenge following vaccination with a live attenuated Venezuelan equine encephalitis virus vaccine.. Vaccine 2000 Sep 15;19(2-3):337-47.
    doi: 10.1016/S0264-410X(00)00123-7pubmed: 10930689google scholar: lookup
  46. Martin SS, Bakken RR, Lind CM, Garcia P, Jenkins E, Glass PJ, Parker MD, Hart MK, Fine DL. Evaluation of formalin inactivated V3526 virus with adjuvant as a next generation vaccine candidate for Venezuelan equine encephalitis virus.. Vaccine 2010 Apr 19;28(18):3143-51.
    doi: 10.1016/j.vaccine.2010.02.056pmc: PMC2857980pubmed: 20193792google scholar: lookup
  47. Martin SS, Bakken RR, Lind CM, Garcia P, Jenkins E, Glass PJ, Parker MD, Hart MK, Fine DL. Comparison of the immunological responses and efficacy of gamma-irradiated V3526 vaccine formulations against subcutaneous and aerosol challenge with Venezuelan equine encephalitis virus subtype IAB.. Vaccine 2010 Jan 22;28(4):1031-40.
    doi: 10.1016/j.vaccine.2009.10.126pmc: PMC2815090pubmed: 19914193google scholar: lookup
  48. Steele KE, Davis KJ, Stephan K, Kell W, Vogel P, Hart MK. Comparative neurovirulence and tissue tropism of wild-type and attenuated strains of Venezuelan equine encephalitis virus administered by aerosol in C3H/HeN and BALB/c mice.. Vet Pathol 1998 Sep;35(5):386-97.
    doi: 10.1177/030098589803500508pubmed: 9754544google scholar: lookup
  49. Klimstra WB, Ryman KD, Johnston RE. Adaptation of Sindbis virus to BHK cells selects for use of heparan sulfate as an attachment receptor.. J Virol 1998 Sep;72(9):7357-66.
    pmc: PMC109960pubmed: 9696832doi: 10.1128/jvi.72.9.7357-7366.1998google scholar: lookup
  50. Paessler S, Ni H, Petrakova O, Fayzulin RZ, Yun N, Anishchenko M, Weaver SC, Frolov I. Replication and clearance of Venezuelan equine encephalitis virus from the brains of animals vaccinated with chimeric SIN/VEE viruses.. J Virol 2006 Mar;80(6):2784-96.
    doi: 10.1128/JVI.80.6.2784-2796.2006pmc: PMC1395430pubmed: 16501087google scholar: lookup
  51. Lennette EH, Koprowski H. Human infection with Venezuelan equine encephalomyelitis virus: A report on eight cases of infection acquired in the laboratory.. JAMA 1943;123:1088–1095.
    doi: 10.1001/jama.1943.02840520004002google scholar: lookup
  52. Rusnak JM, Dupuy LC, Niemuth NA, Glenn AM, Ward LA. Comparison of Aerosol- and Percutaneous-acquired Venezuelan Equine Encephalitis in Humans and Nonhuman Primates for Suitability in Predicting Clinical Efficacy under the Animal Rule.. Comp Med 2018 Oct 1;68(5):380-395.
    doi: 10.30802/AALAS-CM-18-000027pmc: PMC6200028pubmed: 30282570google scholar: lookup
  53. Beck CE, Wyckoff RW. VENEZUELAN EQUINE ENCEPHALOMYELITIS.. Science 1938 Dec 2;88(2292):530.
    doi: 10.1126/science.88.2292.530pubmed: 17840536google scholar: lookup
  54. McCurdy K, Joyce J, Hamilton S, Nevins C, Sosna W, Puricelli K, Rayner JO. Differential accumulation of genetic and phenotypic changes in Venezuelan equine encephalitis virus and Japanese encephalitis virus following passage in vitro and in vivo.. Virology 2011 Jun 20;415(1):20-9.
    doi: 10.1016/j.virol.2011.03.030pubmed: 21507450google scholar: lookup
  55. Peters CJ, Dalrymple JM. Alphaviruses. Fields Virology 1990;3rd ed.;pp. 713–759.
  56. Casals J, Curnen EC, Thomas L. VENEZUELAN EQUINE ENCEPHALOMYELITIS IN MAN.. J Exp Med 1943 Jun 1;77(6):521-30.
    doi: 10.1084/jem.77.6.521pmc: PMC2135362pubmed: 19871301google scholar: lookup
  57. KOPROWSKI H, COX HR. Human laboratory infection with Venezuelan equine encephalomyelitis virus; report of four cases.. N Engl J Med 1947 May 1;236(18):647-54.
    doi: 10.1056/NEJM194705012361801pubmed: 20295009google scholar: lookup
  58. SLEPUSHKIN AN. Epidemiological studies on case of Venezuelan equine encephalomyelitis in a laboratory.. Vopr Virusol 1959 May-Jun;4(3):311-4.
    pubmed: 13676464
  59. SUTTON LS, BROOKE CC. Venezuelan equine encephalomyelitis due to vaccination in man.. J Am Med Assoc 1954 Aug 21;155(17):1473-6.
    doi: 10.1001/jama.1954.03690350015005pubmed: 13183767google scholar: lookup
  60. Franck PT, Johnson KM. An outbreak of Venezuelan encephalitis in man in the Panamá Canal Zone.. Am J Trop Med Hyg 1970 Sep;19(5):860-5.
    doi: 10.4269/ajtmh.1970.19.860pubmed: 5453912google scholar: lookup
  61. Charles PC, Walters E, Margolis F, Johnston RE. Mechanism of neuroinvasion of Venezuelan equine encephalitis virus in the mouse.. Virology 1995 Apr 20;208(2):662-71.
    doi: 10.1006/viro.1995.1197pubmed: 7747437google scholar: lookup
  62. Ryzhikov AB, Tkacheva NV, Sergeev AN, Ryabchikova EI. Venezuelan equine encephalitis virus propagation in the olfactory tract of normal and immunized mice.. Biomed Sci 1991;2(6):607-14.
    pubmed: 1841630
  63. Vogel P, Abplanalp D, Kell W, Ibrahim MS, Downs MB, Pratt WD, Davis KJ. Venezuelan equine encephalitis in BALB/c mice: kinetic analysis of central nervous system infection following aerosol or subcutaneous inoculation.. Arch Pathol Lab Med 1996 Feb;120(2):164-72.
    pubmed: 8712896
  64. Steele KE, Twenhafel NA. REVIEW PAPER: pathology of animal models of alphavirus encephalitis.. Vet Pathol 2010 Sep;47(5):790-805.
    doi: 10.1177/0300985810372508pubmed: 20551475google scholar: lookup
  65. Danes L, Kufner J, Hrusková J, Rychterová V. The role of the olfactory route on infection of the respiratory tract with Venezuelan equine encephalomyelitis virus in normal and operated Macaca rhesus monkeys. I. Results of virological examination.. Acta Virol 1973 Jan;17(1):50-6.
    pubmed: 4405396
  66. Danes L, Rychterová V, Kufner J, Hrusková J. The role of the olfactory route on infection of the respiratory tract with Venezuelan equine encephalomyelitis virus in normal and operated Macaca rhesus monkeys. II. Results of histological examination.. Acta Virol 1973 Jan;17(1):57-60.
    pubmed: 4405397
  67. TASKER JB, MIESSE ML, BERGE TO. Studies on the virus of Venezuelan equine encephalomyelitis. III. Distribution in tissues of experimentally infected mice.. Am J Trop Med Hyg 1962 Nov;11:844-50.
    doi: 10.4269/ajtmh.1962.11.844pubmed: 13993424google scholar: lookup
  68. SMITH DG, MAMAY HK, MARSHALL RG, WAGNER JC. Venezulean equine encephalomyelitis; laboratory aspects of fourteen human cases following vaccination and attempts to isolate the virus from the vaccine.. Am J Hyg 1956 Mar;63(2):150-64.
    doi: 10.1093/oxfordjournals.aje.a119800pubmed: 13302205google scholar: lookup
  69. Yu GY, Wiley MR, Kugelman JR, Ladner JT, Beitzel BF, Eccleston LT, Morazzani EM, Glass PJ, Palacios GF. Complete coding sequences of eastern equine encephalitis virus and venezuelan equine encephalitis virus strains isolated from human cases.. Genome Announc 2015 Apr 23;3(2).
    doi: 10.1128/genomeA.00243-15pmc: PMC4408325pubmed: 25908124google scholar: lookup
  70. de la Monte S, Castro F, Bonilla NJ, Gaskin de Urdaneta A, Hutchins GM. The systemic pathology of Venezuelan equine encephalitis virus infection in humans.. Am J Trop Med Hyg 1985 Jan;34(1):194-202.
    doi: 10.4269/ajtmh.1985.34.194pubmed: 3918474google scholar: lookup
  71. Food and Drug Administration-Center for Biologics Evaluation and Research (FDA-CBER). Development of a Western, Eastern, and Venezuelan Equine Encephalitis (WEVEEV) Vaccine, Animal Model Strain Selection, Version 1.0. Apr 20, 2015.
  72. Pratt WD, Gibbs P, Pitt ML, Schmaljohn AL. Use of telemetry to assess vaccine-induced protection against parenteral and aerosol infections of Venezuelan equine encephalitis virus in non-human primates.. Vaccine 1998 May-Jun;16(9-10):1056-64.
    doi: 10.1016/S0264-410X(97)00192-8pubmed: 9682359google scholar: lookup
  73. Aronson JF, Grieder FB, Davis NL, Charles PC, Knott T, Brown K, Johnston RE. A single-site mutant and revertants arising in vivo define early steps in the pathogenesis of Venezuelan equine encephalitis virus.. Virology 2000 Apr 25;270(1):111-23.
    doi: 10.1006/viro.2000.0241pubmed: 10772984google scholar: lookup
  74. Grieder FB, Davis NL, Aronson JF, Charles PC, Sellon DC, Suzuki K, Johnston RE. Specific restrictions in the progression of Venezuelan equine encephalitis virus-induced disease resulting from single amino acid changes in the glycoproteins.. Virology 1995 Feb 1;206(2):994-1006.
    doi: 10.1006/viro.1995.1022pubmed: 7856110google scholar: lookup
  75. Davis NL, Willis LV, Smith JF, Johnston RE. In vitro synthesis of infectious venezuelan equine encephalitis virus RNA from a cDNA clone: analysis of a viable deletion mutant.. Virology 1989 Jul;171(1):189-204.
    doi: 10.1016/0042-6822(89)90526-6pubmed: 2525837google scholar: lookup
  76. Davis NL, Powell N, Greenwald GF, Willis LV, Johnson BJ, Smith JF, Johnston RE. Attenuating mutations in the E2 glycoprotein gene of Venezuelan equine encephalitis virus: construction of single and multiple mutants in a full-length cDNA clone.. Virology 1991 Jul;183(1):20-31.
    doi: 10.1016/0042-6822(91)90114-Qpubmed: 2053280google scholar: lookup
  77. Davis NL, Grieder FB, Smith JF, Greenwald GF, Valenski ML, Sellon DC, Charles PC, Johnston RE. A molecular genetic approach to the study of Venezuelan equine encephalitis virus pathogenesis.. Arch Virol Suppl 1994;9:99-109.
    doi: 10.1007/978-3-7091-9326-6pubmed: 8032286google scholar: lookup
  78. Ryzhikov AB, Ryabchikova EI, Sergeev AN, Tkacheva NV. Spread of Venezuelan equine encephalitis virus in mice olfactory tract.. Arch Virol 1995;140(12):2243-54.
    doi: 10.1007/BF01323243pubmed: 8572944google scholar: lookup
  79. Rossi SL, Russell-Lodrigue KE, Killeen SZ, Wang E, Leal G, Bergren NA, Vinet-Oliphant H, Weaver SC, Roy CJ. IRES-Containing VEEV Vaccine Protects Cynomolgus Macaques from IE Venezuelan Equine Encephalitis Virus Aerosol Challenge.. PLoS Negl Trop Dis 2015 May;9(5):e0003797.
    doi: 10.1371/journal.pntd.0003797pmc: PMC4447396pubmed: 26020513google scholar: lookup
  80. Reed DS, Lind CM, Lackemeyer MG, Sullivan LJ, Pratt WD, Parker MD. Genetically engineered, live, attenuated vaccines protect nonhuman primates against aerosol challenge with a virulent IE strain of Venezuelan equine encephalitis virus.. Vaccine 2005 May 2;23(24):3139-47.
    doi: 10.1016/j.vaccine.2004.12.023pubmed: 15837213google scholar: lookup
  81. Dupuy LC, Richards MJ, Reed DS, Schmaljohn CS. Immunogenicity and protective efficacy of a DNA vaccine against Venezuelan equine encephalitis virus aerosol challenge in nonhuman primates.. Vaccine 2010 Oct 28;28(46):7345-50.
    doi: 10.1016/j.vaccine.2010.09.005pubmed: 20851089google scholar: lookup
  82. Pratt WD, Davis NL, Johnston RE, Smith JF. Genetically engineered, live attenuated vaccines for Venezuelan equine encephalitis: testing in animal models.. Vaccine 2003 Sep 8;21(25-26):3854-62.
    doi: 10.1016/S0264-410X(03)00328-1pubmed: 12922119google scholar: lookup
  83. Weaver SC, Klimstra WB. Personal communication. 2019.
  84. Brittingham K, Garver JN, Cauthon AG, Sabourin CL, Burback BL. Evaluation of the Median Lethal Dose (LD50) of Venezuelan Equine Encephalitis Virus in BALB/c Mice. .
  85. Coffey LL, Beeharry Y, Bordería AV, Blanc H, Vignuzzi M. Arbovirus high fidelity variant loses fitness in mosquitoes and mice.. Proc Natl Acad Sci U S A 2011 Sep 20;108(38):16038-43.
    doi: 10.1073/pnas.1111650108pmc: PMC3179076pubmed: 21896755google scholar: lookup
  86. Warmbrod KL, Patterson EI, Kautz TF, Stanton A, Rockx-Brouwer D, Kalveram BK, Khanipov K, Thangamani S, Fofanov Y, Forrester NL. Viral RNA-dependent RNA polymerase mutants display an altered mutation spectrum resulting in attenuation in both mosquito and vertebrate hosts.. PLoS Pathog 2019 Apr;15(4):e1007610.
    doi: 10.1371/journal.ppat.1007610pmc: PMC6467425pubmed: 30947291google scholar: lookup
  87. Burke DS, Ramsburg HH, Edelman R. Persistence in humans of antibody to subtypes of Venezuelan equine encephalomyelitis (VEE) virus after immunization with attenuated (TC-83) VEE virus vaccine.. J Infect Dis 1977 Sep;136(3):354-9.
    doi: 10.1093/infdis/136.3.354pubmed: 903673google scholar: lookup
  88. Forrester NL, Wertheim JO, Dugan VG, Auguste AJ, Lin D, Adams AP, Chen R, Gorchakov R, Leal G, Estrada-Franco JG, Pandya J, Halpin RA, Hari K, Jain R, Stockwell TB, Das SR, Wentworth DE, Smith MD, Kosakovsky Pond SL, Weaver SC. Evolution and spread of Venezuelan equine encephalitis complex alphavirus in the Americas.. PLoS Negl Trop Dis 2017 Aug;11(8):e0005693.
    doi: 10.1371/journal.pntd.0005693pmc: PMC5557581pubmed: 28771475google scholar: lookup
  89. Rico AB, Phillips AT, Schountz T, Jarvis DL, Tjalkens RB, Powers AM, Olson KE. Venezuelan and western equine encephalitis virus E1 liposome antigen nucleic acid complexes protect mice from lethal challenge with multiple alphaviruses.. Virology 2016 Dec;499:30-39.
    doi: 10.1016/j.virol.2016.08.023pmc: PMC5884135pubmed: 27632563google scholar: lookup
  90. Hart MK, Lind C, Bakken R, Robertson M, Tammariello R, Ludwig GV. Onset and duration of protective immunity to IA/IB and IE strains of Venezuelan equine encephalitis virus in vaccinated mice.. Vaccine 2001 Nov 12;20(3-4):616-22.
    doi: 10.1016/S0264-410X(01)00337-1pubmed: 11672929google scholar: lookup
  91. Schmaljohn AL, Johnson ED, Dalrymple JM, Cole GA. Non-neutralizing monoclonal antibodies can prevent lethal alphavirus encephalitis.. Nature 1982 May 6;297(5861):70-2.
    doi: 10.1038/297070a0pubmed: 6280072google scholar: lookup

Citations

This article has been cited 13 times.
Subscribe to our newsletter
Join 99,911 horse owners like you who receive our email updates on horse health and nutrition.